Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander

被引:65
作者
Vanni, Ester [1 ]
Marengo, Andrea [1 ]
Mezzabotta, Lavinia [1 ]
Bugianesi, Elisabetta [1 ]
机构
[1] Univ Torino, AO Citta Salute & Sci Torino, Dept Med Sci, Div Gastrohepatol, I-10126 Turin, Italy
关键词
nonalcoholic fatty liver disease; metabolic syndrome; cardiovascular disease; type 2 diabetes mellitus; colorectal cancer; chronic kidney disease; CHRONIC KIDNEY-DISEASE; GAMMA-GLUTAMYL-TRANSFERASE; TYPE-2; DIABETIC-PATIENTS; LEFT-VENTRICULAR FUNCTION; INDEPENDENT RISK-FACTOR; CORONARY-HEART-DISEASE; TERM-FOLLOW-UP; INSULIN-RESISTANCE; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME;
D O I
10.1055/s-0035-1562944
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The top three leading causes of death in patients with nonalcoholic fatty liver disease (NAFLD) in descending order are cardiovascular disease, cancer, and liver disease. It is clear now that the increased risk of metabolic and macro-and microvascular complications in NAFLD stems from the associated features of metabolic syndrome. However, NAFLD itself may contribute to the spectrum of risk factors associated with insulin resistance. The primary focus of this review is to summarize the main systemic associations of NAFLD, as well as to discuss the mechanisms that link them to NAFLD. Hepatic lipid accumulation in NAFLD impairs hepatic glucose and lipid metabolism further increasing the risk of type 2 diabetes mellitus and of cardiovascular disease, independently of established risk factors. The incidence, prevalence, and severity of these complications are proportional to the histological severity of liver damage suggesting that NAFLD, but particularly nonalcoholic steatohepatitis, can also contribute to the low-grade inflammatory state through the systemic release of several markers of inflammation, oxidative stress, and of procoagulant factors. The clinical implication of these findings is that patients with NAFLD require a multidisciplinary evaluation, with a major focus on type 2 diabetes mellitus and cardiovascular disease complications and may benefit from more intensive surveillance and early treatment interventions to decrease the risk for cardiovascular and kidney complications.
引用
收藏
页码:236 / 249
页数:14
相关论文
共 50 条
  • [21] Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD
    Lonardo, Amedeo
    Sookoian, Silvia
    Chonchol, Michel
    Loria, Paola
    Targher, Giovanni
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (29) : 5177 - 5192
  • [22] Nonalcoholic fatty liver disease and lipids
    Wierzbicki, Anthony S.
    Oben, Jude
    CURRENT OPINION IN LIPIDOLOGY, 2012, 23 (04) : 345 - 352
  • [23] Pediatric Nonalcoholic Fatty Liver Disease
    Bozic, Molly A.
    Subbarao, Girish
    Molleston, Jean P.
    NUTRITION IN CLINICAL PRACTICE, 2013, 28 (04) : 448 - 458
  • [24] Nonalcoholic fatty liver disease and statins
    Tziomalos, Konstantinos
    Athyros, Vasilios G.
    Paschos, Paschalis
    Karagiannis, Asterios
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2015, 64 (10): : 1215 - 1223
  • [25] Nonalcoholic fatty liver disease and cardiovascular disease
    Liu, Hong
    Lu, Hong-Yun
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (26) : 8407 - 8415
  • [26] Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders
    Lim, Soo
    Oh, Tae Jung
    Koh, Kwang Kon
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 201 : 408 - 414
  • [27] Extra-Hepatic Manifestations of Nonalcoholic Fatty Liver Disease: A Review
    Tariq, Raseen
    Axley, Page
    Singal, Ashwani K.
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2020, 10 (01) : 81 - 87
  • [28] Nonalcoholic fatty liver disease
    Erickson, Sandra K.
    JOURNAL OF LIPID RESEARCH, 2009, 50 : S412 - S416
  • [29] Dyslipidemia in Patients with Nonalcoholic Fatty Liver Disease
    Chatrath, Hemant
    Vuppalanchi, Raj
    Chalasani, Naga
    SEMINARS IN LIVER DISEASE, 2012, 32 (01) : 22 - 29
  • [30] Epigenetics factors in nonalcoholic fatty liver disease
    Pirola, Carlos Jose
    Sookoian, Silvia
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (06) : 521 - 536